Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Piper raises Apollo Endosurgery target to $7 after FDA breakthrough designation » 10:46
03/01/21
03/01
10:46
03/01/21
10:46
APEN

Apollo Endosurgery

$5.51 /

+0.76 (+16.00%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder raised the firm's price target on Apollo Endosurgery to $7 from $6 and keeps an Overweight rating on the shares after the company received FDA Breakthrough Device Designation for its Orbera Intragastric Balloon for treating non-cirrhotic nonalcoholic steatohepatitis, or NASH, with liver fibrosis in certain patients. While admitting "there's still more work to be done here," Maeder said the designation is "a nice endorsement" of the potential role Orbera could play in NASH with liver fibrosis patients and helps validate the product's broader utility beyond its current primary use for aesthetic weight loss.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$5.51 /

+0.76 (+16.00%)

APEN Apollo Endosurgery
$5.51 /

+0.76 (+16.00%)

02/08/21 Piper Sandler
Apollo Endo's new CEO a 'strong fit to take the reins,' says Piper Sandler
12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
APEN Apollo Endosurgery
$5.51 /

+0.76 (+16.00%)

APEN Apollo Endosurgery
$5.51 /

+0.76 (+16.00%)

Hot Stocks
Apollo Endosurgery receives breakthrough device designation for Orbera balloon » 06:39
03/01/21
03/01
06:39
03/01/21
06:39
APEN

Apollo Endosurgery

$4.70 /

+0.13 (+2.84%)

Apollo Endosurgery…

Apollo Endosurgery announced that it has received a breakthrough device designation from the FDA for the Orbera Intragastric Balloon, specifically for the indication for use in treating patients with BMI between 30-40 kg/m2 with noncirrhotic nonalcoholic steatohepatitis, or NASH, with liver fibrosis.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$4.70 /

+0.13 (+2.84%)

APEN Apollo Endosurgery
$4.70 /

+0.13 (+2.84%)

02/08/21 Piper Sandler
Apollo Endo's new CEO a 'strong fit to take the reins,' says Piper Sandler
12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
APEN Apollo Endosurgery
$4.70 /

+0.13 (+2.84%)

APEN Apollo Endosurgery
$4.70 /

+0.13 (+2.84%)

Over a week ago
Recommendations
Apollo Endo's new CEO a 'strong fit to take the reins,' says Piper Sandler » 13:05
02/08/21
02/08
13:05
02/08/21
13:05
APEN

Apollo Endosurgery

$5.21 /

+0.43 (+9.00%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder reiterates an Overweight rating on Apollo Endosurgery after the company announced that Charles McKhann will replace current CEO Todd Newton, saying that while the news comes "as a bit of a surprise," the transition was carefully planned and had been in the works for some time. Maeder believes McKhann's past experiences make him a strong fit to take the reins and continues to like the set-up, the analyst tells investors in a research note.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$5.21 /

+0.43 (+9.00%)

APEN Apollo Endosurgery
$5.21 /

+0.43 (+9.00%)

12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
APEN Apollo Endosurgery
$5.21 /

+0.43 (+9.00%)

APEN Apollo Endosurgery
$5.21 /

+0.43 (+9.00%)

Hot Stocks
Apollo Endosurgery: Charles McKhann to succeed Todd Newton as CEO » 13:02
02/08/21
02/08
13:02
02/08/21
13:02
APEN

Apollo Endosurgery

$5.20 /

+0.42 (+8.79%)

Apollo Endosurgery…

Apollo Endosurgery announced a planned CEO change. Effective March 1, 2021, Charles "Chas" McKhann will become CEO and a member of the Board of Directors. Current CEO Todd Newton will help facilitate an effective transition to McKhann and has agreed to serve as a consultant to the company for up to 6 months following his transition. John Barr, Chairman of Apollo's Board of Directors, commented, "We are pleased to announce Chas' appointment, and we want to thank Todd for his excellent stewardship. While Todd's achievements are many, his leadership during the COVID-19 pandemic has been particularly notable. In the past year, Todd's timely decision making has resulted in a leaner company, with a materially stronger balance sheet. He has built a robust foundation for the next stage of Apollo's growth. On a path to profitability, driven by continued strong sales of OverStitch and Orbera, and with the recent approval and upcoming full commercial launch of X-Tack, we felt the time was appropriate to transition to a new leader."

ShowHide Related Items >><<
APEN Apollo Endosurgery
$5.20 /

+0.42 (+8.79%)

APEN Apollo Endosurgery
$5.20 /

+0.42 (+8.79%)

12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
APEN Apollo Endosurgery
$5.20 /

+0.42 (+8.79%)

APEN Apollo Endosurgery
$5.20 /

+0.42 (+8.79%)

Options
new option listings on February 3rd » 08:30
02/03/21
02/03
08:30
02/03/21
08:30
AACQ

Artius Acquisition

$10.81 /

+0.07 (+0.65%)

, ADTX

Aditx Therapeutics

$3.20 /

-0.07 (-2.14%)

, AMCI

AMCI Acquisition Corp

$16.55 /

-0.52 (-3.05%)

, APEN

Apollo Endosurgery

$4.44 /

+0.13 (+3.02%)

, CABA

Cabaletta Bio

$12.85 /

+0.05 (+0.39%)

, CRSA

Crescent Acquisition

$10.39 /

-0.01 (-0.10%)

, EQOS

Diginex

$15.75 /

+0.35 (+2.27%)

, EVGN

Evogene

$6.65 /

+0.23 (+3.58%)

, EVLO

Evelo Biosciences

$16.47 /

-0.22 (-1.32%)

, EXPC

Experience Investment Corp.

$15.46 /

+0.04 (+0.26%)

, FRSX

Foresight Autonomous

$8.64 /

+0.37 (+4.47%)

, FSDC

FS Development

$13.24 /

+0.25 (+1.92%)

, FSRV

FinServ Acquisition Corp

$16.65 /

-0.79 (-4.53%)

, FUSE

Fuisz Technologies

$12.01 /

+0.01 (+0.08%)

, FUSN

Fusion Pharmaceuticals

$11.68 /

+0.26 (+2.28%)

, IZEA

Izea

$5.23 /

+0.52 (+11.04%)

, LOV

Spark Networks

$5.78 /

+0.28 (+5.09%)

, NPA

New Providence Acquisition Corp.

$14.38 /

+ (+0.00%)

, NRBO

NeuroBo Pharmaceuticals

$5.21 /

-0.08 (-1.51%)

, SHLS

Shoals Technologies

$38.84 /

+1.04 (+2.75%)

, TBA

Thoma Bravo Advantage

$11.97 /

-0.03 (-0.25%)

, UAVS

Ageagle Aerial Systems

$11.06 /

-0.43 (-3.74%)

, XM

Qualtrics

$51.23 /

+2.52 (+5.17%)

New option listings for…

New option listings for February 3rd include Artius Acquisition Inc (Class A Stock) (AACQ), ADiTx Therapeutics Inc (ADTX), AMCI Acquisition Corporation (Class A Stock) (AMCI), Apollo Endosurgery (APEN), Cabaletta Bio Inc (CABA), CITIC Capital Acquisition Corp (Class A Stock) (CCAC), Crescent Acquisition Corporation (Class A Stock) (CRSA), Diginex Ltd (EQOS), Evogene (EVGN), Evelo Biosciences Inc (EVLO), Experience Investment Corporation (Class A Stock) (EXPC), Fortress Value Acquisition Corp II (Class A Stock) (FAII), Foresight Autonomous Holdings Ltd (ADS) (FRSX), FS Development Corporation (Class A Stock) (FSDC), FinServ Acquisition Corporation (Class A Stock) (FSRV), Fusion Acquisition Corp (Class A Stock) (FUSE), Fusion Pharmaceuticals Inc (FUSN), IZEA (IZEA), Spark Networks Plc (ADS) (LOV), New Povidence Acquisition Corporation (Class A Stock) (NPA), NeuroBo Pharmaceuticals (NRBO), CC Neuberger Principal Holdings II (Class A Stock) (PRPB), Shoals Technologies Group Inc (Class A Stock) (SHLS), Sustainable Opportunities Acquisition Corp (Class A Stock) (SOAC), Silver Spike Acquisition Corporation (Class A Stock) (SSPK), Thoma Bravo Advantage (Class A Stock) (TBA), Tuscan Holdings Corporation II (THCA), AgEagle Aerial Systems Inc (UAVS), Vanguard Long Term Government Bond (VGLT), Vanguard Emerging Markets Government Bond (VWOB), and Qualtrics International Inc (Class A Stock) (XM).

ShowHide Related Items >><<
XM Qualtrics
$51.23 /

+2.52 (+5.17%)

UAVS Ageagle Aerial Systems
$11.06 /

-0.43 (-3.74%)

NRBO NeuroBo Pharmaceuticals
$5.21 /

-0.08 (-1.51%)

NPA New Providence Acquisition Corp.
$14.38 /

+ (+0.00%)

LOV Spark Networks
$5.78 /

+0.28 (+5.09%)

IZEA Izea
$5.23 /

+0.52 (+11.04%)

FUSN Fusion Pharmaceuticals
$11.68 /

+0.26 (+2.28%)

FSRV FinServ Acquisition Corp
$16.65 /

-0.79 (-4.53%)

FRSX Foresight Autonomous
$8.64 /

+0.37 (+4.47%)

EXPC Experience Investment Corp.
$15.46 /

+0.04 (+0.26%)

EVLO Evelo Biosciences
$16.47 /

-0.22 (-1.32%)

EVGN Evogene
$6.65 /

+0.23 (+3.58%)

EQOS Diginex
$15.75 /

+0.35 (+2.27%)

CRSA Crescent Acquisition
$10.39 /

-0.01 (-0.10%)

CABA Cabaletta Bio
$12.85 /

+0.05 (+0.39%)

APEN Apollo Endosurgery
$4.44 /

+0.13 (+3.02%)

AMCI AMCI Acquisition Corp
$16.55 /

-0.52 (-3.05%)

ADTX Aditx Therapeutics
$3.20 /

-0.07 (-2.14%)

AACQ Artius Acquisition
$10.81 /

+0.07 (+0.65%)

ADTX Aditx Therapeutics
$3.20 /

-0.07 (-2.14%)

AMCI AMCI Acquisition Corp
$16.55 /

-0.52 (-3.05%)

APEN Apollo Endosurgery
$4.44 /

+0.13 (+3.02%)

12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
CABA Cabaletta Bio
$12.85 /

+0.05 (+0.39%)

01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
CRSA Crescent Acquisition
$10.39 /

-0.01 (-0.10%)

EQOS Diginex
$15.75 /

+0.35 (+2.27%)

EVGN Evogene
$6.65 /

+0.23 (+3.58%)

11/30/20 Cantor Fitzgerald
Cantor Fitzgerald starts 'highly underappreciated' Evogene at Overweight
11/30/20 Cantor Fitzgerald
Evogene initiated with an Overweight at Cantor Fitzgerald
EVLO Evelo Biosciences
$16.47 /

-0.22 (-1.32%)

01/25/21 JMP Securities
Evelo Biosciences price target raised to $36 from $27 at JMP Securities
12/30/20 JMP Securities
Evelo shares undervalued into atopic dermatitis data, says JMP Securities
12/23/20 JMP Securities
Evelo Biosciences initiated with an Outperform at JMP Securities
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
EXPC Experience Investment Corp.
$15.46 /

+0.04 (+0.26%)

FRSX Foresight Autonomous
$8.64 /

+0.37 (+4.47%)

01/05/21 Alliance Global Partners
Foresight Autonomous price target raised to $5.25 from $2.50 at Alliance Global
10/15/20 Aegis
Foresight Autonomous initiated with a Buy at Aegis
05/19/20 Alliance Global Partners
Foresight Autonomous initiated with a Buy at Alliance Global Partners
FSDC FS Development
$13.24 /

+0.25 (+1.92%)

FSRV FinServ Acquisition Corp
$16.65 /

-0.79 (-4.53%)

FUSE Fuisz Technologies
$12.01 /

+0.01 (+0.08%)

FUSN Fusion Pharmaceuticals
$11.68 /

+0.26 (+2.28%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Morgan Stanley
Fusion Pharmaceuticals initiated with an Overweight at Morgan Stanley
07/21/20 Wedbush
Wedbush bullish on Fusion Pharmaceuticals, initiates with an Outperform
07/21/20 Jefferies
Fusion Pharmaceuticals initiated with a Buy at Jefferies
IZEA Izea
$5.23 /

+0.52 (+11.04%)

01/26/21
Fly Intel: Top five analyst downgrades
01/26/21 Ladenburg
Ladenburg downgrades Izea to Sell on 'excessive' valuation
01/26/21 Ladenburg
Izea downgraded to Sell from Neutral at Ladenburg
11/13/20 Ladenburg
Izea downgraded to Neutral on 'muted' bookings growth at Ladenburg
LOV Spark Networks
$5.78 /

+0.28 (+5.09%)

08/28/20 B. Riley Securities
Spark Networks price target raised to $10 from $8 at B. Riley FBR
08/28/20 Canaccord
Spark Networks price target lowered to $9 from $19 at Canaccord
04/30/20 B. Riley Securities
Spark Networks price target lowered to $7.50 from $11 at B. Riley FBR
04/21/20 B. Riley Securities
Spark Networks price target lowered to $11 from $17.50 at B. Riley FBR
NPA New Providence Acquisition Corp.
$14.38 /

+ (+0.00%)

NRBO NeuroBo Pharmaceuticals
$5.21 /

-0.08 (-1.51%)

02/01/21 H.C. Wainwright
NeuroBo Pharmaceuticals price target lowered to $16 from $20 at H.C. Wainwright
06/15/20 H.C. Wainwright
NeuroBo Pharmaceuticals initiated with a Buy at H.C. Wainwright
02/18/20 Ladenburg
NeuroBo Pharmaceuticals initiated with a Buy at Ladenburg
SHLS Shoals Technologies
$38.84 /

+1.04 (+2.75%)

TBA Thoma Bravo Advantage
$11.97 /

-0.03 (-0.25%)

UAVS Ageagle Aerial Systems
$11.06 /

-0.43 (-3.74%)

XM Qualtrics
$51.23 /

+2.52 (+5.17%)

NRBO NeuroBo Pharmaceuticals
$5.21 /

-0.08 (-1.51%)

FUSN Fusion Pharmaceuticals
$11.68 /

+0.26 (+2.28%)

EVLO Evelo Biosciences
$16.47 /

-0.22 (-1.32%)

CABA Cabaletta Bio
$12.85 /

+0.05 (+0.39%)

APEN Apollo Endosurgery
$4.44 /

+0.13 (+3.02%)

ADTX Aditx Therapeutics
$3.20 /

-0.07 (-2.14%)

  • 29
    Jan
  • 27
    Jan
  • 30
    Jun
  • 25
    Jun
  • 26
    Jun
  • 28
    Jan
XM Qualtrics
$51.23 /

+2.52 (+5.17%)

TBA Thoma Bravo Advantage
$11.97 /

-0.03 (-0.25%)

XM Qualtrics
$51.23 /

+2.52 (+5.17%)

TBA Thoma Bravo Advantage
$11.97 /

-0.03 (-0.25%)

SHLS Shoals Technologies
$38.84 /

+1.04 (+2.75%)

IZEA Izea
$5.23 /

+0.52 (+11.04%)

FSRV FinServ Acquisition Corp
$16.65 /

-0.79 (-4.53%)

NRBO NeuroBo Pharmaceuticals
$5.21 /

-0.08 (-1.51%)

Over a month ago
Conference/Events
Apollo Endosurgery management to meet virtually with Piper Sandler » 04:55
01/28/21
01/28
04:55
01/28/21
04:55
APEN

Apollo Endosurgery

$4.50 /

-0.19 (-4.05%)

Virtual Meeting to be…

Virtual Meeting to be held on January 28 hosted by Piper Sandler.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$4.50 /

-0.19 (-4.05%)

APEN Apollo Endosurgery
$4.50 /

-0.19 (-4.05%)

12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
APEN Apollo Endosurgery
$4.50 /

-0.19 (-4.05%)

Conference/Events
Apollo Endosurgery management to meet virtually with Piper Sandler » 10:13
01/27/21
01/27
10:13
01/27/21
10:13
APEN

Apollo Endosurgery

$4.30 /

-0.39 (-8.32%)

Virtual Meeting to be…

Virtual Meeting to be held on January 28 hosted by Piper Sandler.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$4.30 /

-0.39 (-8.32%)

APEN Apollo Endosurgery
$4.30 /

-0.39 (-8.32%)

12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
APEN Apollo Endosurgery
$4.30 /

-0.39 (-8.32%)

Hot Stocks
Apollo Endosurgery gets FDA clearance for X-Tack Endoscopic HeliX Tacking System » 16:47
12/15/20
12/15
16:47
12/15/20
16:47
APEN

Apollo Endosurgery

$3.90 /

-0.01 (-0.26%)

Apollo Endosurgery…

Apollo Endosurgery announced that the U.S. Food and Drug Administration 510k clearance of the X-Tack Endoscopic HeliX Tacking System. X-Tack is a new, through-the-scope, suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract with additional applications in the upper gastrointestinal tract. The X-Tack device enables physicians to easily address the challenges commonly encountered when closing large or irregularly shaped defects. The procedure involves suture-tethered HeliX Tacks, independently positioned into healthy tissue adjacent to a defect, then cinched to close the construct. X-Tack fulfills a long-expressed need for advanced closure devices to improve healing and address potential adverse events that can occur following colonic polypectomy and mucosal resections, such as delayed bleeding or perforation. Apollo plans to initiate a limited launch with select gastroenterologists beginning January 2021, to be followed by a full launch planned for late in the quarter of 2021. "The X-Tack System fills a substantial gap in the ability of endoscopists to close full thickness defects, particularly large or irregular colonic and small bowel resection sites. It has the potential for making a significant impact in other procedures as well," says, Stavros Stavropoulos, MD, Director of Endoscopy, NYU-Winthrop Hospital. "X-Tack is a highly versatile technology that has the potential to revolutionize our tissue approximation capabilities during endoscopic surgery.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$3.90 /

-0.01 (-0.26%)

APEN Apollo Endosurgery
$3.90 /

-0.01 (-0.26%)

12/07/20 Piper Sandler
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler
11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
APEN Apollo Endosurgery
$3.90 /

-0.01 (-0.26%)

Recommendations
Apollo Endosurgery looks to boost liquidity with loan deal, says Piper Sandler » 10:45
12/07/20
12/07
10:45
12/07/20
10:45
APEN

Apollo Endosurgery

$3.82 /

+ (+0.00%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder says Apollo Endosurgery's agreement with Solar Capital to extend the interest-only period and maturity date of its existing term loan provides the company with additional liquidity and we think should be positively received by shareholders. The analyst says Apollo has sufficient cash to execute on its game plan in 2021, which he thinks is shaping up to be a strong year behind the positive underlying momentum in the business and the upcoming launch of X-Tack. The analyst made no change to his Overweight rating or $5 price target.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$3.82 /

+ (+0.00%)

APEN Apollo Endosurgery
$3.82 /

+ (+0.00%)

11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
APEN Apollo Endosurgery
$3.82 /

+ (+0.00%)

Hot Stocks
Apollo Endosurgery amends loan and security agreement with Solar Capital » 10:45
12/07/20
12/07
10:45
12/07/20
10:45
APEN

Apollo Endosurgery

$3.82 /

+ (+0.00%)

In a regulatory filing,…

In a regulatory filing, Apollo Endosurgery disclosed that on December 4, the company and Solar Capital Ltd. entered into a seventh amendment to their loan and security agreement dated March 15, 2019, or the term loan facility. The amendment extends the interest only period available under the facility until March 1, 2022, or September 1, 2022 if certain revenue milestones are achieved, extends the maturity date of the facility to September 1, 2024, or March 1, 2025 if certain revenue milestones are achieved, and resets mandatory prepayment fees as of the date of the seventh amendment. In addition, in connection with the amendment, the final fee due at maturity and the additional fee due at the earlier of certain exit events or achievement of certain revenue milestones were increased by 2% and 1%, respectively, the company stated in a regulatory filing.

ShowHide Related Items >><<
APEN Apollo Endosurgery
$3.82 /

+ (+0.00%)

APEN Apollo Endosurgery
$3.82 /

+ (+0.00%)

11/30/20 Piper Sandler
Apollo Endosurgery upgraded to Overweight from Neutral at Piper Sandler
04/28/20 Piper Sandler
Apollo Endosurgery downgraded to Neutral from Overweight at Piper Sandler
03/27/20 Piper Sandler
Apollo Endosurgery price target lowered to $4.50 from $5.50 at Piper Sandler
APEN Apollo Endosurgery
$3.82 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.